Another bispecific, humanized IgG1 antibody that is definitely below investigation is zenocutuzumab (MCLA-128), which acts via two independent mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells via ADCC. MCLA-128 capabilities by means of a ‘dock and block’ system whereby a single arm with the antibody binds https://www.directivepublications.org/journal-of-clinical-breast-cancer/